Get the Weekly Intelligence Brief — top committee picks every Sunday.
A · NASDAQ · STOCK

Agilent Technologies

Healthcare Updated August 09, 2026
$148.07
52W $108.35 – $160.27
65/100
$41.23B
29.3
1.23
AI Committee Verdict
Buy
65/100
Conviction: High · 83% agreement · 6 analysts
+2.0%
-1.9%
1.07:1
High

Is A Bullish or Bearish?

Bullish. Innellis AI committee rates Agilent Technologies (A) Buy with a composite score of 65/100 , based on 6 analysts with 83% agreement. Last updated August 09, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +10.33 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -9.67 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The primary driver is news sentiment is positive (+0.40 across 26 articles, 14d). The main limiting factor is p/e of 29.2 is moderate-to-rich. The committee is constructive but not yet at full conviction.

Bull & Bear Case

Bull Case
  • ROE of 20.8% shows genuine earnings power backing the valuation — Value
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • P/E of 29.2 is moderate-to-rich — Value
  • Price-to-book of 6.2x prices in significant intangible value — Value
  • RSI at 79 is in overbought territory — Technical
  • Price trading above the upper Bollinger Band -- stretched — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 09, 2026
Overall Committee Score
65/100
Agreement
83%
Analysts
6
Conviction
High
Sector Rank
Top 18%
of 95 Healthcare peers
Value Analyst neutral
54 / 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 20.8% shows genuine earnings power backing the valuation
− P/E of 29.2 is moderate-to-rich
Growth Analyst bullish
62 / 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst bullish
61 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− RSI at 79 is in overbought territory
Risk Analyst bullish
70 / 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
Macro Analyst bullish
70 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst bullish
70 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.40 across 26 articles, 14d)
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 4 existing position pair(s) are highly correlated already
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 64.7 to 64.7.

Analyst-level changes:
  • News Analyst: +1 bullish signal(s).

Comparing 2026-08-08 to 2026-08-09 (1 day apart).

Technical Analysis

RSI (14)
79.0
Overbought
MACD Histogram
0.472
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Support
$143.38
Resistance
$148.99
Bollinger %B
1.05
Above Upper Band
Price vs Moving Averages
EMA 9
$140.76 Above
EMA 21
$137.92 Above
EMA 50
$133.29 Above
EMA 200
$128.63 Above

Fundamental Analysis

Valuation
54
Growth
59
Profitability
94
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio 29.3×
P/B Ratio 5.80×
PEG Ratio 1.29
Dividend Yield 0.69%
52W High $160.27
52W Low $108.35
Quality & Growth
ROE 1933.0%
ROA 1023.8%
Gross Margin 5300.1%
Operating Margin 2150.2%
Revenue Growth YoY
Debt / Equity 0.47
AI Fundamental Assessment
P/E ratio of 29.3 (moderate relative to a 15-40x range); Price-to-book of 5.8x; PEG ratio of 1.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 19.3%; Return on assets of 10.2%; Net margin of 19.6%; Gross margin of 53.0%; Current ratio of 2.10 (healthy short-term liquidity); Debt-to-equity of 0.47; Free cash flow per share is positive (4.44); Most recent quarter beat estimates by 3.8%; EPS growth accelerating (-14.5% -> +9.6% QoQ); Analyst estimates falling over recent quarters
Get the Full A Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore A Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime